Custom mRNA vaccine aims to stop liver cancer recurrence after surgery

NCT ID NCT07495215

Recruiting now Disease control Sponsor: Yinghua Xu Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized mRNA vaccine (iNeo-Vac-R01) made from each patient's tumor, combined with an immunotherapy drug (PD-1 inhibitor), to prevent liver cancer from coming back after surgery. About 20 adults with early-stage liver cancer will receive the treatment. The goal is to see if it is safe and can extend the time without cancer returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital
RECRUITING

Hangzhou, Zhejiang, 310016, China

Contact Phone: •••-•••-•••• Email: •••••@•••••